Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variant

Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variant

BackgroundNirmatrelvir-ritonavir is an oral treatment for SARS-CoV-2 infection in patients who are at high risk of developing severe COVID-19 disease. This antiviral has proven to significantly reduce the risk of hospitalization and death compared to no anti-SARS-CoV-2 treatment in this target popul...

Full description

Saved in:
Bibliographic Details
Main Authors: Sophie Marbaix, Steven Simoens, Philippe Clevenbergh, Pascal Van Bleyenbergh, Keliane Liberman, Dimitri Dehenau
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Public Health
Subjects:
cost-utility
SARS-CoV-2
antiviral treatment
Belgium
high-risk persons
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2024.1432821/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2024.1432821/full

Similar Items